143 related articles for article (PubMed ID: 36549594)
21. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
22. IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results.
Cragun D; Beckstead J; Farmer M; Hooker G; Dean M; Matloff E; Reid S; Tezak A; Weidner A; Whisenant JG; Pal T
BMC Cancer; 2021 Oct; 21(1):1099. PubMed ID: 34645413
[TBL] [Abstract][Full Text] [Related]
23. Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
Sarki M; Ming C; Aissaoui S; Bürki N; Caiata-Zufferey M; Erlanger TE; Graffeo-Galbiati R; Heinimann K; Heinzelmann-Schwarz V; Monnerat C; Probst-Hensch N; Rabaglio M; Zürrer-Härdi U; Chappuis PO; Katapodi MC; On Behalf Of The Cascade Consortium
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406409
[TBL] [Abstract][Full Text] [Related]
24. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
Frey MK; Ahsan MD; Bergeron H; Lin J; Li X; Fowlkes RK; Narayan P; Nitecki R; Rauh-Hain JA; Moss HA; Baltich Nelson B; Thomas C; Christos PJ; Hamilton JG; Chapman-Davis E; Cantillo E; Holcomb K; Kurian AW; Lipkin S; Offit K; Sharaf RN
J Clin Oncol; 2022 Dec; 40(35):4129-4143. PubMed ID: 35960887
[TBL] [Abstract][Full Text] [Related]
25. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
26. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA
Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
[TBL] [Abstract][Full Text] [Related]
27. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
[TBL] [Abstract][Full Text] [Related]
28. Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling.
Pfledderer CD; Gren LH; Frost CJ; Andrulis IL; Chung WK; Genkinger J; Glendon G; Hopper JL; John EM; Southey M; Terry MB; Daly MB
J Genet Couns; 2022 Dec; 31(6):1249-1260. PubMed ID: 35794807
[TBL] [Abstract][Full Text] [Related]
29. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women.
Thompson HS; Valdimarsdottir HB; Duteau-Buck C; Guevarra J; Bovbjerg DH; Richmond-Avellaneda C; Amarel D; Godfrey D; Brown K; Offit K
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1579-85. PubMed ID: 12496047
[TBL] [Abstract][Full Text] [Related]
30. Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.
Obstet Gynecol; 2019 Dec; 134(6):1366-1367. PubMed ID: 31764755
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
Garcia C; Sullivan MW; Lothamer H; Harrison KM; Chatfield L; Thomas MH; Modesitt SC
J Obstet Gynaecol Res; 2020 Sep; 46(9):1835-1841. PubMed ID: 32656916
[TBL] [Abstract][Full Text] [Related]
32. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
[TBL] [Abstract][Full Text] [Related]
33. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
34. Impact of BRCA1/2 cascade testing on anxiety, depression, and cancer worry levels among unaffected relatives in a multiethnic Asian cohort.
Padmanabhan H; Mariapun S; Lee SY; Hassan NT; Lee DS; Meiser B; Wong SW; Lee YQ; Yip CH; Teo SH; Thong MK; Taib NAM; Yoon SY
J Genet Couns; 2023 Feb; 32(1):43-56. PubMed ID: 35913122
[TBL] [Abstract][Full Text] [Related]
35. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
36. Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication.
Pollard S; Kalloger S; Weymann D; Sun S; Nuk J; Schrader KA; Regier DA
Health Expect; 2020 Aug; 23(4):884-892. PubMed ID: 32338425
[TBL] [Abstract][Full Text] [Related]
37. Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information.
Himes DO; Clayton MF; Donaldson GW; Ellington L; Buys SS; Kinney AY
J Genet Couns; 2016 Apr; 25(2):258-69. PubMed ID: 26245632
[TBL] [Abstract][Full Text] [Related]
38. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
39. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
[TBL] [Abstract][Full Text] [Related]
40. Healthcare Professionals' Learning Needs and Perspectives on Essential Information in Genetic Cancer Care: A Systematic Review.
Park SY; Kim Y; Katapodi MC; Kim YJ; Chae H; Choi YJ; Ryu KH; Lee EG; Kong SY; Jung SY
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
